ClinicalTrials.gg
TerminatedNCT06128044AMpLifyUpdated Jun 11, 2025

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of CB-012 in Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by Caribou Biosciences, Inc.. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Caribou Biosciences, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor Decision - Pipeline Reprioritization

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,539th of 1,908
12 · median 35
Started
2024
with 70 others
Phase 1
772 of 2,138
127 open now
Registered
1,938th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,539th largest by enrollment of the 1,908 interventional ones that give a count, is one of 71 that started in 2024, is one of 772 in phase 1, and was the 1,938th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of treatment for AML .

03

Conditions studied

  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of AML with either or relapsed disease,
  • Non-proliferative disease
  • No more than 3 (induction, consolidation with or without stem cell transplant, and maintenance are considered 1 line of therapy)
  • No available therapy with reasonable survival benefit
  • (ECOG) performance status grade of 0 or 1 and fit for allogeneic stem cell transplant
  • Adequate renal, hepatic, pulmonary, and cardiac function, with specific laboratory criteria
  • Women of and men with a female partner who has child-bearing potential must agree to use acceptable, effective methods of .

Exclusion criteria

Exclusion Criteria:

  • Acute promyelocytic leukemia
  • Extra-medullary disease (EMD) that is metabolically inactive by 18-FDG PET-CT
  • Prior treatment with CAR-T cell therapy
  • stem cell transplant within 100 days before lymphodepletion
  • Active graft-vs-host disease requiring therapy
  • Known active or prior history of central nervous system involvement
  • Seropositive for or history of (HIV)
  • Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion
  • Active or C infection
  • Primary immunodeficiency or disease
  • Known life-threatening allergies, , or intolerance to CB-012 or its

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Dose Escalation of CB-012

    Part A (Dose Escalation) of CB-012 with increasing doses using a 3+3 design, during which the MTD and/or RDE will be identified.

    Drug: CB-012

  • Experimental
    Dose Expansion of CB-012

    Part B (Dose Expansion) - participants will be enrolled to receive CB-012 at the RDE and/or MTD determined in Part A in order to the determine the RP2D.

    Drug: CB-012

Interventions

  • DrugCB-012

    CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion

    Also known as: Cyclophosphamide, Fludarabine

06

What researchers measure

Primary outcomes

  1. (Part A) Number of patients with dose limiting toxicities (DLT)

    Number of patients with DLTs during the 28 days following the first administration of CB-012.

    Time frame: 28 days

  2. (Part B) Overall Response Rate (ORR)

    The ORR will be evaluated by European Leukemia Net (ELN) criteria

    Time frame: 12 months

07

Study locations

10 sites
  • The University of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35249-0001, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • The Blood & Marrow Transplant Group of Georgia (BMTGA)
    Atlanta, Georgia 30342, United States
  • Weill Cornell Medical College
    New York, New York 10022, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC)
    New York, New York 10065, United States
  • TriStar Bone Marrow Transplant, LLC
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109-1023, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in May 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 13, 2023
StartActual
Feb 8, 2024
Primary completionActual
May 30, 2025
CompletionActual
May 30, 2025
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06128044
Lead sponsor
Caribou Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Feb 8, 2024
Primary completion
May 30, 2025
Completion
May 30, 2025
Last update
Jun 11, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion